About Akamis Bio
Clinical-stage oncology company using a proprietary Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to deliver novel immunotherapeutic proteins, biomolecules and transgene combinations to treat solid tumors.
Sectors & Market Categories
Company Details
Corporate & Operational Profile
Primary Industry
Biotech & Healthcare
Funding Stage
Series-A
Global Headquarters
Cambridge, United States
Year Founded
2009
Team Size
11-50
Tracked Since
Oct 1, 2026
Web & Domain Identity
Official Website
akamisbio.com
Domain Registered Date
Nov 14, 2022
Social & Network Presence
LinkedIn Corporate
Not linked
Company Milestones & Timeline
- Capital Raise
Raised $60,000,000 · Series-A
fundraisingfox.com
- Milestone
Website domain registered
akamisbio.com
- Milestone
X account created (@AkamisBio)
1.0K followers
- Milestone
Company founded
Cambridge, United States
Investors & Backers
ARCH Venture Partners
Bristol-Myers Squibb
Imperial Innovations
IP Group
Lundbeckfonden Ventures
Parker Institute for Cancer Immunotherapy
Salica
Sedgwick Yard
Westlake Village BioPartners
Woodford Investment Management
Funding History
Series-A
· Dec 17, 2024
$60,000,000 fundraisingfox.com
Founders & Leadership
Andrew Coats
Founder
Work email & phone locked
Unlock →
Howard Davis
Chief Executive Officer
Work email & phone locked
Unlock →
John Beadle
Founder
Work email & phone locked
Unlock →
Kerry Fisher
Founder
Work email & phone locked
Unlock →
Priya Mande
Chief Operating Officer and U.K. President
Work email & phone locked
Unlock →
Tom Lillie
Chief Medical Officer
Work email & phone locked
Unlock →
Press Coverage & Sources
Recently Funded Biotech & Healthcare Startups
View allVitalls
vitalls.ai
Seed Abu Dhabi, United Arab Emirates · Oct 2026
Hexagon Bio
hexagonbio.com
Series-B+ Oct 2026
RefloDx
reflodx.com
Seed Kaysville, United States · Oct 2026
HeyVoli
heyvoli.com
Pre-Seed Bangalore, India · Oct 2026
CureBay
curebay.com
Series-B+ Bhubaneshwar, India · Oct 2026
4Tissue
4tissue.com
Series-A Ghent, Belgium · Oct 2026